Professor Ronald F. van Vollenhoven, MD, PhD

Professor Ronald F. van Vollenhoven, MD, PhD

Amsterdam Rheumatology and Immunology Center, Amsterdam,
The Netherlands

Ronald F van Vollenhoven is the Director of the Amsterdam Rheumatology and Immunology Center and Chief of the Department of Rheumatology and Clinical Immunology at the Academic Medical Center, and the Department of Rheumatology at Vrije Universiteit Medical Center in Amsterdam, the Netherlands. He is also Chair of the Rheumatology Research Council at Reade, and continues some of his responsibilities as Chief of the Unit for Clinical Therapy Research (ClinTRID) at the Karolinska Institute.

He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he did immunology research at Cornell Medical College in New York, followed by in Internal Medicine at the State University of New York at Stony Brook, and a fellowship in Rheumatology at Stanford University in Palo Alto following which he received American Board of Internal Medicine certification in both Internal Medicine and Rheumatology.

From 1993 to 1998 Professor van Vollenhoven was Assistant Professor of Medicine and then Medical Services Chief and Fellowship Director in the Division of Immunology and Rheumatology at Stanford University.

In 1998 Professor van Vollenhoven moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; and in 2010, he was appointed as Professor and Unit Chief at the Karolinska Institute.

Professor van Vollenhoven’s research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database), which supports research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the recently published SWEFOT trial. He has published over 260 original papers (H-index: 56), book chapters and reviews, and is editor and author of several text books. In 2004, Professor van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology. He is the Editor-in-Chief of Lupus Science & Medicine, Chair of the EULAR Standing Committee on Clinical Affairs, member of many editorial boards, past-Chair of the Swedish Rheumatology Society Professors’ Council, co-Founder of the IRBIS registry for biologics in SLE, the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE initiative.

Disclosures

Grants/Research Support: AbbVie; Amgen; BMS; GSK; Pfizer; Roche; UCB
Meeting Honorarium/Expenses: AbbVie; Biotest; BMS; Crescendo; GSK; Janssen; Eli Lilly; Merck; Pfizer; Roche; UCB; Vertex

Professor van Vollenhoven is co-Chair of the Lupus Academy Annual Meeting (2016) and has been involved in the planning and development of the 5th Annual Meeting programme and materials.

Secretariat
Lupus Academy Foundation
Maasdijk 409
4264 AS Veen
The Netherlands
Tel: +31 (0) 416 693 925
Email: secretariat@lupus-academy.org